BR0314965A - Derivados de 2-oxodiidropiridina n-substituìdos - Google Patents

Derivados de 2-oxodiidropiridina n-substituìdos

Info

Publication number
BR0314965A
BR0314965A BR0314965-0A BR0314965A BR0314965A BR 0314965 A BR0314965 A BR 0314965A BR 0314965 A BR0314965 A BR 0314965A BR 0314965 A BR0314965 A BR 0314965A
Authority
BR
Brazil
Prior art keywords
alkyl
alkylamino
hydroxy
alkoxy
halogen
Prior art date
Application number
BR0314965-0A
Other languages
English (en)
Inventor
Nagaaki Sato
Makoto Ando
Shiho Ishikawa
Tsuyoshi Nagase
Keita Nagai
Akio Kanatani
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of BR0314965A publication Critical patent/BR0314965A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE 2-OXODIIDROPIRIDINA N-SUBSTITUìDOS". A presente invenção se refere a um composto de fórmula (I): (em que Ar^ 1^ e Ar^ 2^ são independentemente arila ou heteroarila, qualquer um dos quais sendo opcionalmente substituído por um substituinte selecionado do grupo que consiste de ciano, halogênio, nitro, alquila inferior, halo-alquila inferior, hidróxi-alquila inferior, ciclo-alquila inferior, ciclo(alquil-inferior)-alquila inferior, alquenila inferior, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, alquilssulfonilamino inferior, arilssulfonilamino inferior, hidróxi, alcóxi inferior, haloalcóxi inferior, arilóxi, heteroarilóxi, alquiltio inferior, carboxila, formila, alcanoíla inferior, alcóxicarbonila inferior, carbamoíla, alquilcarbamoíla inferior, di-alquilcarbamoíla inferior, alquilssulfonila inferior, arilssulfonila, arila e heteroarila; R^ 1^ e R^ 2^ são independentemente alquila inferior, ciclo-alquila inferior, ciclo(alquil-inferior)-alquila inferior ou alcóxi inferior, qualquer um dos quais sendo opcionalmente substituído por um substituinte selecionado do grupo que consiste de halogênio, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, hidróxi, alcóxi inferior, formila, alcóxicarbonila inferior, alquilcarbamoíla inferior e dialquilcarbamoíla inferior; R^ 3^ R^ 4^ e R^ 5^ são independentemente hidrogênio, ciano, halogênio, hidróxi, ou alquila inferior, alcóxi inferior ou alquiltio inferior, os últimos três grupos sendo opcionalmente substituídos por um substituinte selecionado do grupo que consiste de halogênio, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, hidróxi, alcóxi inferior, formila, alcóxicarbonila inferior, alquilcarbamoíla inferior e di-alquilcarbamoíla inferior), ou um sal ou éster do mesmo, em que tais compostos são de utilidade como agentes antagonistas do receptor do neuropeptídeo Y e também de utilidade como agentes destinados ao tratamento de bulimia, obesidade ou diabetes.
BR0314965-0A 2002-09-30 2003-09-25 Derivados de 2-oxodiidropiridina n-substituìdos BR0314965A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002287015 2002-09-30
JP2002353202 2002-12-05
PCT/JP2003/012290 WO2004031175A2 (en) 2002-09-30 2003-09-25 N-substituted-2-oxodihydropyridine derivatives as npy antagonists

Publications (1)

Publication Number Publication Date
BR0314965A true BR0314965A (pt) 2005-08-02

Family

ID=32072466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314965-0A BR0314965A (pt) 2002-09-30 2003-09-25 Derivados de 2-oxodiidropiridina n-substituìdos

Country Status (17)

Country Link
US (2) US6869966B2 (pt)
EP (1) EP1546133B1 (pt)
KR (1) KR20050059217A (pt)
CN (1) CN100528864C (pt)
AR (1) AR041374A1 (pt)
AT (1) ATE461191T1 (pt)
AU (1) AU2003273522B2 (pt)
BR (1) BR0314965A (pt)
CA (2) CA2726754C (pt)
DE (1) DE60331751D1 (pt)
MX (1) MXPA05003293A (pt)
NO (1) NO20052106L (pt)
PE (1) PE20050087A1 (pt)
PL (1) PL376475A1 (pt)
RU (1) RU2005113310A (pt)
TW (1) TW200407138A (pt)
WO (1) WO2004031175A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4887139B2 (ja) * 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0413452A (pt) * 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US7790734B2 (en) * 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
FR2861302A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861301B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861300B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134231B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1753730A1 (en) * 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP2805953B1 (en) * 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ES2445180T5 (es) * 2005-09-14 2022-02-01 Takeda Pharmaceuticals Co Administración de inhibidores de dipeptidil peptidasa
CA2622472C (en) * 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CN102675221A (zh) * 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007115967A1 (en) * 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Crystalline isopropanol solvate of glucokinase activator
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
JP5635991B2 (ja) 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． イソニコチンアミドオレキシン受容体アンタゴニスト
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2684102C2 (ru) * 2014-04-09 2019-04-04 Дженентек, Инк. Способ получения лекарственных средств
CN112047889A (zh) * 2018-11-30 2020-12-08 华南农业大学 一种n-二氟甲基杂芳烃并咪唑硫脲衍生物的制备方法
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4200295A1 (en) 2020-08-18 2023-06-28 Merck Sharp & Dohme LLC Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH234887A (de) * 1942-12-11 1944-10-31 Ag J R Geigy Verfahren zur Herstellung von N-Cyclohexyl-6-pyridon-3-carbonsäurediäthylamid.
CZ403592A3 (en) * 1992-02-20 1993-12-15 Hoechst Ag Arylcarbonylaminoalkyldihydrooxopyridines, process of their preparation and their use
AU757290B2 (en) 1998-03-25 2003-02-13 Bristol-Myers Squibb Company Imidazolone anorectic agents: II. phenyl derivatives
US7064142B2 (en) * 2000-02-22 2006-06-20 Banyu Pharmaceutical, Co., Ltd. Imidazonline compounds

Also Published As

Publication number Publication date
US7138525B2 (en) 2006-11-21
CA2726754C (en) 2013-04-02
EP1546133B1 (en) 2010-03-17
WO2004031175A2 (en) 2004-04-15
AU2003273522B2 (en) 2009-05-21
CN1684954A (zh) 2005-10-19
MXPA05003293A (es) 2005-10-18
CA2497237C (en) 2011-03-29
PL376475A1 (en) 2005-12-27
CA2497237A1 (en) 2004-04-15
NO20052106L (no) 2005-04-29
DE60331751D1 (de) 2010-04-29
US20050009879A1 (en) 2005-01-13
EP1546133A2 (en) 2005-06-29
RU2005113310A (ru) 2005-11-10
US20040072874A1 (en) 2004-04-15
KR20050059217A (ko) 2005-06-17
TW200407138A (en) 2004-05-16
CA2726754A1 (en) 2004-04-15
US6869966B2 (en) 2005-03-22
CN100528864C (zh) 2009-08-19
AU2003273522A1 (en) 2004-04-23
AR041374A1 (es) 2005-05-11
WO2004031175A3 (en) 2005-02-24
PE20050087A1 (es) 2005-02-22
ATE461191T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
BR0314965A (pt) Derivados de 2-oxodiidropiridina n-substituìdos
BR0013041A (pt) Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método
NO20023218L (no) 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer
AR042450A1 (es) Indazolilpirrolotriazinas modificadas c-6
TW200633991A (en) Chemical compounds
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
UY26089A1 (es) Inhibidores de la sorbitol deshidrogenasa
MA30709B1 (fr) Derives de pyrido (2, 3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3.
KR20110042374A (ko) Ｍｉｆ 조정인자
UA99822C2 (ru) Производные изоксазолина, композиции для борьбы с бесхребетным вредителем, способ борьбы с бесхребетным вредителем и способ защиты животного от бесхребетного паразитарного вредителя
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
EP1783116A4 (en) 2-PHENYLPYRIDINE DERIVATIVE
WO2009068531A3 (en) Adamantyl o-glucuronide derivatives as inhibitors of dipeptidyl peptidase iv for the treatment of diabetes
TNSN07348A1 (en) Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
EA200802052A1 (ru) 2-(пиридин-2-ил)-пиримидины в качестве фунгицидов
CR9710A (es) Proceso para la preparacion de ciertos derivados de fenilpropargileter
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
ATE505457T1 (de) Isochinoline als igf-1r-inhibitoren
ES2074544T3 (es) Derivados de naftiloxazolidona.
BR112023002080A2 (pt) Sirna modificado com atividade fora do alvo reduzida
PE20060103A1 (es) Nuevas 5-acilindolinonas con contenido en cicloalquilo y su preparacion como medicamento

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]